Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2002

View Archived Issues

Efficacy and safety of glucagon antagonist demonstrated in early clinical trial

Spotlight on tPA and stroke at ISC

Repligen highlights the progress of its two lead programs

Tumor-targeting polymer conjugate will be codeveloped by Tanabe and Menarini

Late administration of NO donor improves outcome in a rat stroke model

MMP inhibitor does not improve the arterial response to angioplasty and stenting in primates

Vical reviews pipeline progress in 2001

Xenical approved in Canada for use in type 2 diabetics

Launch of delayed-release oral suspension formulation of Prevacid

Approvable letter issued by FDA for Remodulin in pulmonary arterial hypertension

Stressgen validates targeting HspE7 at genital warts market

Roche and Vernalis enter R&D agreement for antiobesity drugs

Estramustine analogues have a promising preclinical profile of antitumor activity

Roche and deCODE enter new drug development alliance

Adenosine derivatives claimed by Pfizer for use in inflammatory respiratory diseases

Yamanouchi synthesizes macrocyclic antitumor agents

Glycolipid derivatives claimed for use as antitumor agents and immunostimulants

Antifungal compound EM-F2300A isolated by Mercian and Eisai

Mutations in optineurin responsible for adult-onset primary open-angle glaucoma

Peptide compounds with fungal adhesion-inhibitory activity

Aurora2 kinase inhibitors patented by AstraZeneca

The novel protein fibrocystin found to be encoded by a mutated gene in ARPKD

Fibrolase derivative under joint development by Hyseq and Amgen as thrombolytic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...